Adriana Foster
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adriana Foster has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
James W. Lomax
Baylor College of Medicine
3 shared publicationsMichelle Trieu
Kaiser Permanente
3 shared publicationsAlexander Gomes de Siqueira
University of Florida, Gainesville, FL 32611, USA
2 shared publicationsAndreea L. Seritan
University of California, San Francisco
2 shared publications- Aniuska M. Luna
Department of Psychiatry & Behavioral Health, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th Street, AHC4 280, Miami, FL, 33199, USA
2 shared publications - Benjamin Lok
University of Florida, Gainesville, USA
2 shared publications
Latest Publications
- 20 November 2025
- Published by Elsevier in Psychiatry Research
- Vol. 356, 116846
Can training clinicians in emotional awareness using virtual patient interactions improve the therapeutic alliance with psychiatric outpatients and reduce suicidal outcomes?
- 20 November 2025
- Published by Elsevier in Psychiatry Research
- Vol. 356, 116846
Can training clinicians in emotional awareness using virtual patient interactions improve the therapeutic alliance with psychiatric outpatients and reduce suicidal outcomes?
- 30 March 2021
- Published by Springer Nature in Academic Psychiatry
- Vol. 45 (3) , 257-261
Teaching Suicide Risk Assessment: Spotlight on the Therapeutic Relationship
- 30 March 2021
- Published by Springer Nature in Academic Psychiatry
- Vol. 45 (3) , 257-261
Teaching Suicide Risk Assessment: Spotlight on the Therapeutic Relationship
- 1 October 2020
- Published by American Psychiatric Association Publishing in FOCUS
- Vol. 18 (4) , 375-385
Antipsychotic Polypharmacy
Physicians who treat patients with schizophrenia frequently encounter complex clinical situations not fully addressed by published treatment guidelines. Some of these situations lead to antipsychot...
- 1 October 2020
- Published by American Psychiatric Association Publishing in FOCUS
- Vol. 18 (4) , 375-385
Antipsychotic Polypharmacy
Physicians who treat patients with schizophrenia frequently encounter complex clinical situations not fully addressed by published treatment guidelines. Some of these situations lead to antipsychot...
- Open Access
- 1 January 2020
- Published by Moscow State University of Psychology and Education in Clinical Psychology and Special Education
- Vol. 9 (3) , 105-126
Case Series of Transcranial Direct Current Stimulation as an Augmentation Strategy for Attention Bias Modification Treatment in Adolescents with Anxiety Disorders
This article presents the results of a case series to assess the feasibility, acceptability, and clinical promise of transcranial Direct Current Stimulation (tDCS) as an augmentation strategy in clinic referred adolescents. Attention Bias Modification Treatment (ABMT) is a computer-based attention-training protocol designed to reduce rapidly deployed attention orienting to threat and thereby reduce anxiety symptom severity. Studies of ABMT reveal overall small to medium effect sizes. Advances in the neural underpinnings of attention to threat and attention-training protocols suggest the potential of tDCS of the dorsolateral prefrontal cortex (dlPFC) as a novel augmentation strategy to enhance ABMT’s efficacy (ABMT + tDCS). However, tDCS has never been tested in a sample of adolescents with anxiety disorders. Six adolescents with a primary anxiety disorder completed all four ABMT + tDCS sessions. Adverse effects were mild and transient. Adolescents and parents independently reported fair to excellent levels of satisfaction. Impairment ratings of the primary anxiety disorder significantly decreased. Further, electrophysiological data recorded via electroencephalography (EEG) suggested decreases in neural resources allocated to threat. These findings support the feasibility, acceptability, and clinical promise of tDCS as an augmentation strategy in adolescents with anxiety disorders, and provide the impetus for further investigation using randomized controlled designs in larger samples.
- 1 January 2020
- Published by Moscow State University of Psychology and Education in Clinical Psychology and Special Education
- Vol. 9 (3) , 105-126
Open AccessCase Series of Transcranial Direct Current Stimulation as an Augmentation Strategy for Attention Bias Modification Treatment in Adolescents with Anxiety Disorders
This article presents the results of a case series to assess the feasibility, acceptability, and clinical promise of transcranial Direct Current Stimulation (tDCS) as an augmentation strategy in clinic referred adolescents. Attention Bias Modification Treatment (ABMT) is a computer-based attention-training protocol designed to reduce rapidly deployed attention orienting to threat and thereby reduce anxiety symptom severity. Studies of ABMT reveal overall small to medium effect sizes. Advances in the neural underpinnings of attention to threat and attention-training protocols suggest the potential of tDCS of the dorsolateral prefrontal cortex (dlPFC) as a novel augmentation strategy to enhance ABMT’s efficacy (ABMT + tDCS). However, tDCS has never been tested in a sample of adolescents with anxiety disorders. Six adolescents with a primary anxiety disorder completed all four ABMT + tDCS sessions. Adverse effects were mild and transient. Adolescents and parents independently reported fair to excellent levels of satisfaction. Impairment ratings of the primary anxiety disorder significantly decreased. Further, electrophysiological data recorded via electroencephalography (EEG) suggested decreases in neural resources allocated to threat. These findings support the feasibility, acceptability, and clinical promise of tDCS as an augmentation strategy in adolescents with anxiety disorders, and provide the impetus for further investigation using randomized controlled designs in larger samples.
- 19 November 2019
- Published by Springer Nature
- p. 127-142
The Empathy Seminar: Building a Strong Foundation for Caregiving Competency
- 19 November 2019
- Published by Springer Nature
- p. 127-142
The Empathy Seminar: Building a Strong Foundation for Caregiving Competency
- Open Access
- 13 August 2019
- Published by Springer Nature in BMC Research Notes
- Vol. 12 (1) , 1
Correction to: Role of empathy in the perception of medical errors in patient encounters: a preliminary study
In the original publication of this article [1], an author name was misspelled.
- 13 August 2019
- Published by Springer Nature in BMC Research Notes
- Vol. 12 (1) , 1
Open AccessCorrection to: Role of empathy in the perception of medical errors in patient encounters: a preliminary study
In the original publication of this article [1], an author name was misspelled.
- Open Access
- 10 June 2019
- Published by Springer Nature in BMC Research Notes
- Vol. 12 (1) , 327
Role of empathy in the perception of medical errors in patient encounters: a preliminary study
Healthcare professionals’ empathy have been empirically demonstrated to decrease the risk of medical errors. Medical errors affect patient’s outcomes and healthcare providers’ well-being. Therefore, the purpose of this study was to determine the relationship between patients’ perception of healthcare providers’ empathy, their intention to adhere to treatment, and their perception of medical errors made. An anonymous survey was emailed to staff at a health center and an urban university in Miami, Florida, USA. A total of 181 participants were enrolled. Participants rating their healthcare provider as high in empathy had 80% lower odds of reporting errors (CI 0.04–0.6). The intention to follow-up with recommendations or return to the provider were not significantly associated with provider’s empathy. Patients of high empathy providers were no more treatment adherent that those who rated their provider with low empathy but were less likely to perceive medical error. Providers’ empathy significantly affected patients’ perception of medical errors. Our results underscore that healthcare curricula need to address the link between empathy and perception of medical errors, including its potential legal implications.
- 10 June 2019
- Published by Springer Nature in BMC Research Notes
- Vol. 12 (1) , 327
Open AccessRole of empathy in the perception of medical errors in patient encounters: a preliminary study
Healthcare professionals’ empathy have been empirically demonstrated to decrease the risk of medical errors. Medical errors affect patient’s outcomes and healthcare providers’ well-being. Therefore, the purpose of this study was to determine the relationship between patients’ perception of healthcare providers’ empathy, their intention to adhere to treatment, and their perception of medical errors made. An anonymous survey was emailed to staff at a health center and an urban university in Miami, Florida, USA. A total of 181 participants were enrolled. Participants rating their healthcare provider as high in empathy had 80% lower odds of reporting errors (CI 0.04–0.6). The intention to follow-up with recommendations or return to the provider were not significantly associated with provider’s empathy. Patients of high empathy providers were no more treatment adherent that those who rated their provider with low empathy but were less likely to perceive medical error. Providers’ empathy significantly affected patients’ perception of medical errors. Our results underscore that healthcare curricula need to address the link between empathy and perception of medical errors, including its potential legal implications.
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 37 (5) , 595-599
Combination Antipsychotic Therapies
Background: Combination antipsychotics (CAs) are prescribed in schizophrenia despite limited evidence of efficacy. To explore the effect of switching from CA to monotherapy, we performed an exploratory analysis of the PROACTIVE (Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared with Injectables: Evaluating Efficacy) study data, in which 305 patients with schizophrenia and schizoaffective disorder were followed for 30 months after randomization to long-acting injectable (LAI) risperidone or second-generation oral antipsychotic (OA). Methods: Patients who entered the PROACTIVE study on CA (n = 50), LAI (n = 20), or OA (n = 206) were compared in terms of time to relapse and clinical measures. Findings: The OA group had significantly fewer hospitalizations than the CA group (P = 0.009) at baseline. In the CA group, 68% patients relapsed versus 53% in the LAI, and 52% in the OA groups. Although there was no significant difference in the relapse rate among groups on χ2 test (χ2 = 3.85, P = 0.146), the log-rank test showed a significant difference among the groups in time to first relapse (χ2 = 6.81, P = 0.033), with significantly longer time to relapse in the OA group (mean, 562.8 days) than in the CA group (mean, 409.5; P = 0.011). The LAI group's mean time to first relapse (594 days) was not significantly different from the other groups. However, after adjusting for number of hospitalizations, group was no longer significant (hazard ratio, 1.541; P = 0.052). Implications: Based on our exploratory analysis, taking antipsychotic combinations predicts earlier relapse and calls for additional treatment guidance in schizophrenia.
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 37 (5) , 595-599
Combination Antipsychotic Therapies
Background: Combination antipsychotics (CAs) are prescribed in schizophrenia despite limited evidence of efficacy. To explore the effect of switching from CA to monotherapy, we performed an exploratory analysis of the PROACTIVE (Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared with Injectables: Evaluating Efficacy) study data, in which 305 patients with schizophrenia and schizoaffective disorder were followed for 30 months after randomization to long-acting injectable (LAI) risperidone or second-generation oral antipsychotic (OA). Methods: Patients who entered the PROACTIVE study on CA (n = 50), LAI (n = 20), or OA (n = 206) were compared in terms of time to relapse and clinical measures. Findings: The OA group had significantly fewer hospitalizations than the CA group (P = 0.009) at baseline. In the CA group, 68% patients relapsed versus 53% in the LAI, and 52% in the OA groups. Although there was no significant difference in the relapse rate among groups on χ2 test (χ2 = 3.85, P = 0.146), the log-rank test showed a significant difference among the groups in time to first relapse (χ2 = 6.81, P = 0.033), with significantly longer time to relapse in the OA group (mean, 562.8 days) than in the CA group (mean, 409.5; P = 0.011). The LAI group's mean time to first relapse (594 days) was not significantly different from the other groups. However, after adjusting for number of hospitalizations, group was no longer significant (hazard ratio, 1.541; P = 0.052). Implications: Based on our exploratory analysis, taking antipsychotic combinations predicts earlier relapse and calls for additional treatment guidance in schizophrenia.